Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Zepatier | Elbasvir/grazoprevir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Orilissa | elagolix | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | |||
| Jublia | efinaconazole | Onychomycosis | Do not reimburse | Complete | ||
| Vyvgart | efgartigimod alfa | Generalized myasthenia gravis (gMG) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Atripla | Efavirenz, emtricitabine, tenofovir disoproxil fumarate | HIV | List with clinical criteria and/or conditions | Complete | ||
| Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | N/A | Complete | ||
| Raptiva | Efalizumab | Psoriasis, moderate to severe chronic plaque | List with clinical criteria and/or conditions | Complete | ||
| Lixiana NVAF | Edoxaban | Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism. | Reimburse with clinical criteria and/or conditions | Complete | ||
| Lixiana VTE | Edoxaban | Venous thromboembolism, treatment and recurrence prevention. | Reimburse with clinical criteria and/or conditions | Complete | ||
| Radicava | edaravone | amyotrophic lateral sclerosis | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 17, 2024